Boothbay Fund Management LLC Sells 63,206 Shares of Pulmonx Co. (NASDAQ:LUNG)

Boothbay Fund Management LLC decreased its holdings in Pulmonx Co. (NASDAQ:LUNG) by 22.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 212,980 shares of the company’s stock after selling 63,206 shares during the period. Boothbay Fund Management LLC owned about 0.54% of Pulmonx worth $1,446,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in LUNG. Geode Capital Management LLC boosted its holdings in shares of Pulmonx by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 892,786 shares of the company’s stock worth $7,403,000 after buying an additional 11,151 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Pulmonx by 44.8% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,941 shares of the company’s stock worth $570,000 after acquiring an additional 25,988 shares during the period. SG Americas Securities LLC grew its position in shares of Pulmonx by 27.0% in the fourth quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Pulmonx by 2.4% during the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company’s stock worth $8,750,000 after purchasing an additional 25,002 shares during the period. Finally, Barclays PLC boosted its stake in Pulmonx by 1.8% in the 3rd quarter. Barclays PLC now owns 94,109 shares of the company’s stock valued at $780,000 after purchasing an additional 1,679 shares during the period. 91.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

LUNG has been the topic of a number of analyst reports. Jefferies Financial Group began coverage on shares of Pulmonx in a research report on Monday, March 10th. They set a “buy” rating on the stock. Morgan Stanley started coverage on Pulmonx in a report on Monday, March 10th. They issued an “equal weight” rating for the company. D. Boral Capital started coverage on Pulmonx in a report on Monday, March 10th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Citigroup initiated coverage on Pulmonx in a research note on Monday, March 10th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, Pulmonx presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Pulmonx Trading Down 0.2 %

LUNG opened at $5.19 on Tuesday. The company has a market cap of $208.88 million, a P/E ratio of -3.60 and a beta of 0.61. The company has a current ratio of 7.70, a quick ratio of 6.77 and a debt-to-equity ratio of 0.40. The company’s 50 day moving average is $6.78 and its 200-day moving average is $6.59. Pulmonx Co. has a 1-year low of $4.15 and a 1-year high of $10.01.

Pulmonx (NASDAQ:LUNG) last issued its earnings results on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million for the quarter, compared to analyst estimates of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Equities research analysts predict that Pulmonx Co. will post -1.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Glendon E. French III sold 20,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total value of $157,000.00. Following the sale, the director now owns 991,974 shares of the company’s stock, valued at $7,786,995.90. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Mehul Joshi sold 14,384 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $7.12, for a total value of $102,414.08. Following the transaction, the chief financial officer now directly owns 113,986 shares of the company’s stock, valued at approximately $811,580.32. This represents a 11.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 145,660 shares of company stock valued at $1,128,484 in the last 90 days. Corporate insiders own 6.80% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.